Observe Medical gets prospectus approval, launches subsequent offering

The Norwegian Financial Supervisory Authority has approved Observe Medical ASA's prospectus for the listing of private placement shares and the launch of a subsequent offering. The private placement, completed on June 11, 2025, raised gross proceeds of NOK 36,445,000 through the issuance of 72,890,000 new shares, which are expected to be listed on Euronext Expand around September 26, 2025.

The subsequent offering aims to issue up to 24,000,000 offer shares at a subscription price of NOK 0.50 per share, matching the private placement price. This could generate NOK 12,000,000 in gross proceeds. The subscription period will run from September 26, 2025, to October 10, 2025.

Eligible shareholders as of June 11, 2025, will receive 3.0695 subscription rights for every existing share held. These rights must be exercised by the deadline or they will lapse. SB1 Markets AS is managing the subsequent offering.